Beam Therapeutics (BEAM) Accumulated Depreciation & Amortization (2019 - 2025)
Beam Therapeutics (BEAM) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $94.1 million as the latest value for Q4 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization rose 30.54% to $94.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $94.1 million, a 30.54% increase, with the full-year FY2025 number at $94.1 million, up 30.54% from a year prior.
- Accumulated Depreciation & Amortization was $94.1 million for Q4 2025 at Beam Therapeutics, up from $77.6 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $94.1 million in Q4 2025 to a low of $10.3 million in Q1 2021.
- A 5-year average of $44.6 million and a median of $39.6 million in 2023 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 94.78% in 2021, then surged 30.54% in 2025.
- Beam Therapeutics' Accumulated Depreciation & Amortization stood at $16.1 million in 2021, then skyrocketed by 87.61% to $30.2 million in 2022, then surged by 66.33% to $50.2 million in 2023, then surged by 43.69% to $72.1 million in 2024, then surged by 30.54% to $94.1 million in 2025.
- Per Business Quant, the three most recent readings for BEAM's Accumulated Depreciation & Amortization are $94.1 million (Q4 2025), $77.6 million (Q1 2025), and $72.1 million (Q4 2024).